Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
| ▸ | HTR5A | P47898 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092063 | 0.85 | KIF11 (0.51) | HDAC1HDAC2HDAC3MAPTKIF11 | |
| SCHEMBL592446 | 0.84 | NQO2 (0.66) | HDAC1HDAC2HDAC3HTR1AADORA3 | |
| SCHEMBL30949380 | 0.83 | MGLL (0.63) | HTR1AADORA3CCKARHTR5ANQO2 | |
| SCHEMBL27964923 | 0.81 | JAK3 (0.50) | HDAC1HDAC2HDAC3HTR1AADORA3 | |
| SCHEMBL30949373 | 0.80 | MEN1 (0.64) | MAPTSMN1; SMN2 | |
| SCHEMBL30949379 | 0.80 | AURKB (0.62) | MAPT | |
| SCHEMBL20557483 | 0.79 | CNR1 (0.68) | — | |
| SCHEMBL30469266 | 0.79 | CNR1 (0.68) | — | |
| SCHEMBL30949376 | 0.79 | AURKB (0.62) | MAPT | |
| SCHEMBL30949383 | 0.79 | NPC1 (0.59) | HTR1AADORA3CCKARHTR5AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203585-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. | 2009-08-13 | — | — | US | disclosed |
| WO-2007130743-A2 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-7294616-B2 | Capreomycin derivatives and their use as antibacterials | ARRAY BIOPHARMA, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| WO-2006052499-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060094644-A1 | Capreomycin derivatives and their use as antibacterials | ARRAY BIOPHARMA, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203585-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | CAPRIN1, NISCH, RPIA | HDAC1 2318/4885HDAC2 1224/4885HDAC3 1872/4885 |
| US-20060094644-A1 | Capreomycin derivatives and their use as antibacterials | SPOUT1, CAPRIN1, FBL | HDAC1 1070/4885HDAC2 1174/4885HDAC3 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.